Vaccines growth offsets Advair generic pain for GSK
25-07-2019
Swiss court mulls extradition of Chinese researcher accused of GSK trade secrets theft
10-07-2019
Willy Barton / Shutterstock.com
Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline (GSK).
In an announcement yesterday, August 27, Ionis said GSK had decided to agree on licensing the programme following positive phase two results.
Chronic hepatitis B is a viral infection of the liver that can lead to significant and potentially fatal health conditions such as liver failure and liver cancer.
As part of the agreement, Ionis is eligible to receive milestone payments of up to $262 million, including a $25 million licence fee, as well as tiered royalties “in the low double digits” on net sales.
According to the press release, GSK is now responsible or all development, regulatory and commercialisation activities and costs.
Brett Monia, chief operating officer at Ionis, said the antisense technology “can potentially deliver a transformative medicine” for sufferers.
He added: "We believe GSK's expertise in infectious diseases makes them the ideal partner to help address this high unmet need."
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
GlaxoSmithKline, Ionis Pharmaceuticals, antisense, chronic hepatitis B, licensing, liver cancer, liver disease, virus
